Orion Biotech Opportunities Corp. Warrant
ORIAW
ORIAW was delisted on the 28th of April, 2023.
0 hedge funds and large institutions have $0 invested in Orion Biotech Opportunities Corp. Warrant in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 25 closing their positions.
100% less funds holding
Funds holding: 25 → 0 (-25)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $648K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 25
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Segantii Capital Management
Hong Kong
|
-$307K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$153K |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$30.6K |
| 4 |
GAM
Gritstone Asset Management
Bethesda,
Maryland
|
-$21.4K |
| 5 |
6CM
683 Capital Management
New York
|
-$19.2K |
ORIAW Hedge Fund Activity: Q2 2023 in Review
0 of the 6,387 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Warrant (ORIAW) for Q2 2023, worth a combined $0 — down 100% from $648K a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ORIAW and 0 opened new positions — a net loss of 25 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Segantii Capital Management, exiting entirely with an estimated $307K sold.
- 0 institutional investors held Orion Biotech Opportunities Corp. Warrant (ORIAW) as of Q2 2023, down from 25 in Q1 2023.
- Funds reported $0 of Orion Biotech Opportunities Corp. Warrant stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Orion Biotech Opportunities Corp. Warrant positions in Q2 2023 and 25 closed out, a net change of -25 holders.
- The largest Orion Biotech Opportunities Corp. Warrant seller in Q2 2023 was Segantii Capital Management, an estimated $307K sold.
Based on aggregated 13F filings for Q2 2023.